Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34259 | 0.98 | GAA (0.48) | GAAMAPT | |
| Water SCHEMBL4672877 | 0.95 | GAA (0.46) | GAAMAPT | |
| Ammonia Solution, Strong SCHEMBL4151802 | 0.95 | GAA (0.46) | GAAMAPT | |
| SCHEMBL29181632 | 0.95 | GAA (0.46) | GAAMAPT | |
| SCHEMBL8654087 | 0.95 | GAA (0.46) | GAAMAPT | |
| Iodide SCHEMBL12466756 | 0.95 | GAA (0.46) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL160640 | 0.95 | GAA (0.46) | GAAMAPT | |
| Water SCHEMBL16465946 | 0.95 | GAA (0.46) | GAAMAPT | |
| Bromide SCHEMBL10654286 | 0.95 | GAA (0.46) | GAAMAPT | |
| SCHEMBL8654084 | 0.95 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072749-B2 | Treatment of age-related macular degeneration | WEINSTOCK JOSEPH (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2222669-B1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-8222245-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (S1P) | GLAXO GROUP LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20100316731-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | WEINSTOCK JOSEPH | 2010-12-16 | — | — | US | disclosed |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2222669-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100174065-A1 | COMPOUNDS | GLAXO GROUP LIMITED (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2170343-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Weinstock, Joseph (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1646623-A2 | 5-H-BENZO[D]NAPHTH[2,1-B]AZEPINE DERIVATIVE AS SELECTIVE D1/D5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005035504-A2 | 5-H -BENZO [D] NAPHTH [2, 1-B] AZEPINE DERIVATIVE AS SELECTIVE D1/D5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075325-A1 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION | 2005-04-07 | — | — | US | disclosed |
| EP-0734398-B1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2002-02-27 | — | — | EP | disclosed |
| US-5773512-A | Compounds and methods | SMITHKLINE BEECHAM CORP. (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0734398-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0734398-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016712-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-06-22 | — | — | WO | disclosed |
| EP-0238281-B1 | SELECTIVE ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0238281-A1 | Selective alpha-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | GAA 4339/4885MAPT 3598/4885 |
| US-20100174065-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | GAA 83/4885MAPT 1092/4885 |
| US-20050075325-A1 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | GPR119, DRD2, OPRL1 | GAA 1019/4885MAPT 2707/4885 |
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | GAA 650/4885MAPT 1926/4885 |
| US-20100316731-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION | AGER, ALDH1A2, PDE6D | GAA 1105/4885MAPT 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.